Every 8-K that Forte Biosciences Inc (FBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBRX filings page.
Forte Biosciences, Inc. (FBRX) has been acquired by argenx BV through a cash tender offer followed by a merger. Avena Merger Sub Inc., a wholly owned subsidiary of argenx, commenced a tender offer at $77.00 per share in cash for all outstanding Forte common shares.
As of one minute after 11:59 p.m. Eastern Time on August 26, 2026, 19,894,879 shares had been validly tendered and not withdrawn, which, together with shares already owned by argenx, represented approximately 87.13% of Forte’s outstanding shares, satisfying all offer conditions. These shares were irrevocably accepted for payment, and on August 27, 2026, the merger was completed under Section 251(h) of the DGCL, making Forte a wholly owned subsidiary of argenx.
Each remaining share (other than specified excluded and appraisal shares) was converted into the right to receive the same $77.00 cash consideration, and holders of outstanding pre-funded warrants became entitled, upon exercise, to receive the merger consideration for the underlying shares. The acquirer used approximately $2.2 billion of cash on hand to fund the offer, equity awards, pre-funded warrants and related payments. Forte has requested that Nasdaq suspend trading and file Form 25 to delist the shares and plans to file Form 15 to terminate registration and suspend its Exchange Act reporting obligations. All pre-merger directors and officers resigned at the effective time and were replaced by the former directors and officers of Purchaser.
Forte Biosciences, Inc. agreed to be acquired by argenx via a two‑step transaction, starting with a cash tender offer at $77.00 per share, implying approximately $2.2 billion in equity value. Forte’s board unanimously recommended that stockholders accept the offer and tender their shares.
The tender offer will start within 10 business days, remain open at least 15 business days, and is conditioned on shares tendered exceeding 50% of those outstanding, Hart‑Scott‑Rodino clearance and other customary conditions, but not on financing. Following a successful offer, a short‑form merger under DGCL Section 251(h) will close at the same cash price, cashing out in‑the‑money options and RSUs and cancelling out‑of‑the‑money options. The merger agreement includes a $65 million termination fee in specified scenarios and a no‑shop with a fiduciary “Superior Offer” exception. Directors and officers holding about 1% of shares signed tender and support agreements. Closing is expected in Q3 2026.
Forte Biosciences reported positive Phase 1b results for FB102 in vitiligo from a double-blind, placebo-controlled study of 43 subjects. Patients were randomized 3:1, with 32 on FB102 and 11 on placebo.
The primary endpoint was facial vitiligo area severity index (FVASI) percent improvement at week 24. In the efficacy-evaluable population, FB102 achieved a 29.6% mean FVASI improvement from baseline versus 7.9% on placebo, for a placebo-adjusted benefit of 21.7 percentage points (p=0.020). Statistically significant separation from placebo emerged by day 64 and continued through week 24 after the 12‑week dosing period.
Subjects with more extensive baseline disease (FVASI ≥0.75) showed a 43.2% mean FVASI improvement at week 24 (p=0.006), with 58.8% reaching FVASI50 and 23.5% reaching FVASI75, compared with 0% on placebo. FB102’s safety profile remained favorable, with only mild to moderate treatment-emergent adverse events and no severe events reported.
Forte Biosciences, Inc. reported results of its 2026 annual stockholder meeting, where stockholders approved an amended and restated 2021 Equity Incentive Plan reserving 5,190,000 shares of common stock for equity awards. The plan allows stock options, stock appreciation rights, restricted stock, restricted stock units, performance units and performance shares for employees, directors and consultants.
As of the April 17, 2026 record date, 20,478,817 shares were outstanding, and 17,766,034 shares were represented at the May 29, 2026 meeting in person or by proxy. Stockholders also elected three directors and approved additional proposals including the equity plan described in the company’s April 29, 2026 proxy statement.
Forte Biosciences reported a larger first quarter 2026 net loss while advancing its lead drug candidate FB102. The company posted a net loss of $22.1 million, or $(1.24) per share, compared with a $15.7 million loss a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $20.5 million, largely from FB102 Phase 2 celiac disease and Phase 1b vitiligo and alopecia areata trials, while general and administrative costs declined to $2.0 million helped by a $2.3 million interim legal settlement payment from an insurance carrier.
The FDA granted FB102 Fast Track Designation in celiac disease, and Forte highlighted upcoming topline data for Phase 1b vitiligo and Phase 2 celiac disease studies. The company held $58.2 million in cash and cash equivalents at March 31, 2026 and subsequently raised $172.5 million in gross proceeds in an April equity offering, issuing 6.6 million additional common shares.
Forte Biosciences, Inc. entered an underwriting agreement for a public offering of 5,709,936 shares of common stock at $26.27 per share, targeting gross proceeds of about $150 million. Underwriters have a 30-day option to buy up to 856,490 additional shares.
The company expects net proceeds of roughly $141 million, or $162 million if the option is fully exercised, after underwriting discounts and commissions. All shares are being sold by Forte, and the deal is expected to close on or about April 10, 2026, subject to customary conditions.
The offering is made under an effective Form S-3 shelf registration. Forte plans to use the cash mainly for working capital and general corporate purposes, including clinical development of its FB102 autoimmune program and related research activities.
Forte Biosciences reported a larger 2025 net loss as it ramped investment in lead drug FB102. Net loss was $69.4 million versus $35.5 million in 2024, or $(4.71) per share versus $(12.17).
Research and development expenses rose to $58.2 million from $21.2 million, mainly from FB102 phase 2 celiac and phase 1b vitiligo and alopecia trials. General and administrative expenses declined to $12.4 million from $15.4 million, helped by lower professional and legal costs.
Forte ended 2025 with $77.0 million in cash and cash equivalents. As of December 31, 2025, there were 12.9 million common shares and 4.9 million prefunded warrants outstanding. The company highlighted multiple FB102 clinical readouts expected in 2026 across celiac disease, vitiligo and alopecia areata.
Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is included as Exhibit 99.1 to the report.
Forte Biosciences (NASDAQ:FBRX) announced a significant public offering of common stock and pre-funded warrants. The company plans to issue 5,630,450 shares at $12.00 per share and 619,606 pre-funded warrants at $11.999 per warrant. The offering, expected to close around June 26, 2025, will generate approximately $75.0 million in gross proceeds (potentially $80.5 million if underwriters exercise their option). Net proceeds of approximately $70.0 million are expected to fund operations into 2027. The offering is being managed by TD Securities, Evercore, Guggenheim Securities, and Chardan Capital Markets.